Anti-HIV drug development: Structural features and limitations of present day drugs and future challenges in the successful HIV/AIDS treatment

Current Pharmaceutical Design

Volumn 19, Issue 10, 2013, Pages 1767-1783

  Kumari, Garima ^a   Singh, Ramendra K ^a  

^a UNIVERSITY OF ALLAHABAD   (India)

Author keywords

AIDS; Drug resistance; Drug targets; HAART; HIV; Pharmacodynamics; Pharmacogenomics; Pharmacokinetics

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1,3 DIDANOSINE; 2',3' DIDEHYDRO 2',3' DIDEOXY 2' FLUORO 5' O PHOSPHONOMETHYLADENOSINE; 8 [(4 AMINOBUTYL)(2 BENZIMIDAZOLYLMETHYL)AMINO] 1,2,3,4 TETRAHYDROQUINOLINE; ABACAVIR; AMDOXOVIR; APRICITABINE; BILR 355 BS; DARUNAVIR; DELAVIRDINE; EFAVIRENZ; ELVITEGRAVIR; ELVUCITABINE; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSDEVIRINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; LAMIVUDINE; LOPINAVIR; MARAVIROC; MIV 150; NEVIRAPINE; PF 232798; PLERIXAFOR; RALTEGRAVIR; RDEA 806; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG STRUCTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; LOW DRUG DOSE; MUTATION; NEPHROTOXICITY; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS MORPHOLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84876731120     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990295     Document Type: Review

References (149)

1. Reeves JD, Dorns RW. Human immunodeficiency virus type 2. J Gen Virol 2002; 83 (Pt 6): 1253-65.
2. Gilbert PB, McKeague IW, Eisen, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22: 573-93.
3. Zhang Z, Schuler T, Zupancic M, Wietgrefe S, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999; 286: 1353-7.
4. Cunningham AL, Donaghy H, Harman AN, Kim M, Turville SG. Manipulation of dendritic cell function by viruses. Curr Opin Microbiol. 2010; 13: 524-9.
5. Pantaleo G, Demarest JF, Schacker T, et al. The quantitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997; 94: 254-8.
6. Lawn SD. AIDS in Africa: the impact of coinfections on the pathogenesis of HIV-1 infection. J Infect 2004; 48: 1-12.
7. Mitsuya H, Popovic M, Yarchoan R, Matsushita S, Gallo RC, Broder S. Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III. Science 1984; 226: 172-4.
8. Broder S, Yarchoan R, Collins JM, Lane HC, et al. Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet 1985; 2: 627-30.
9. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 1985; 82: 7096-100.
10. Paredes R, Clotet B. Clinical management of HIV-1 resistance. Ant Res 2010; 85: 245-65.
11. Hammer SM, Eron Jr JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-70.
12. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358: 2095-106.
13. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev Drug Discov. 2003; 2: 624-34.
14. Martinez-Picado J, De Pasquale MP, Kartsonis N. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA 2000; 97: 10948-53.
15. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
16. Freed EO, Martin MA. HIVs and their replication. In: Knipe, D.M., Howley, P.M. (Eds.), Fields Virology. Lippincott, Williams and Wilkins, 2007; pp. 2107-85.
17. Doms RW. Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection. Virology 2000; 276 (2): 229-37.
18. Roux KH, Taylor KA. AIDS virus envelope spike structure. Curr Opin Struct Biol 2007; 17 (2): 244-52.
19. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700.
20. Melikyan GB. Common principles and intermediates of viral proteinmediated fusion: the HIV-1 paradigm. Retrovirology 2008; 5: 111.
21. Adamson CS, Freed EO. HIV-1 assembly, release and maturation. In: Jeang, K.-T. (Ed.), Advances in Pharmacolgy, HIV-1: Molecular Biology and Pathogenesis: Viral Mechansims, vol. 55. Elsevier 2007.
22. Ganser-Pornillos BK, von Schwedler UK, Stray KM, Aiken C, Sundquist WI. Assembly properties of the human immunodeficiency virus type 1 CA protein. J Virol 2004; 78(5): 2545-52.
23. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 2009; 385 (3): 693-713.
24. Suzuki Y, Craigie R. The road to chromatin-nuclear entry of retroviruses. Nat Rev Microbiol 2007; 5(3): 187-96.
25. Vandegraaff N, Engelman A. Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev Mol Med 2007; 9(6): 1-19.
26. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 2008; 5: 114.
27. Poeschla EM. Integrase, LEDGF/p75 and HIV replication. Cell Mol Life Sci 2008; 65 (9): 1403-24.
28. Rabson AB, Graves BJ. Synthesis and processing of viral RNA. In: Coffin, JM, Hughes, SH, Varmus, HE Ed. Retroviruses. Cold Spring Harbor Laboratory Press 1997.
29. Swanstrom, R, Wills JW. Synthesis, assembly and processing of viral proteins. In: Coffin JM, Hughes SH, Varmus HE Ed. Retroviruses. Cold Spring Harbor Laboratory Press 1997.
30. Bolinger C, Boris-Lawrie K. Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome. Retrovirology 2009; 6: 8.
31. Nekhai S, Jeang KT. Transcriptional and post-transcriptional regulation of HIV-1 gene expression: role of cellular factors for Tat and Rev. Future Microbiol. 2006; 1: 417-26.
32. Bieniasz PD. The cell biology of HIV-1 virion genesis. Cell Host Microbe 2009; 5(6): 550-8.
33. Fujii K, Hurley JH, Freed EO. Beyond Tsg101: the role of Alix in ESCRTing' HIV-1. Nat Rev Microbiol 2007; 5(12): 912-6.
34. Morita E, Sundquist WI. Retrovirus budding. Annu Rev Cell Dev Biol 2004; 20: 395-425.
35. Ganser-Pornillos BK, Yeager M, Sundquist WI. The structural biology of HIV assembly. Curr. Opin. Struct. Biol. 2008; 18(2): 203-17.
36. McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: Bringing a new era of antiretroviral therapy. Ant Res 2010; 85: 101-18.
37. Matthews T, Salgo M, Greenberg, M, Chung J, DeMasi R, Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Dis 2004; 3: 215-25.
38. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res. Hum. Retroviruses 1993; 9: 1051-3.
39. Ernst JT, Kutzki O, Debnath AK, Jiang S, Lu H, Hamilton AD. Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed 2002; 41: 278-81.
40. Berger EA, Doms RW, Fenyo EM et al. A new classification for HIV-1. Nature 1998; 392: 240.
41. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427, 857), a potent, orally bioavailable and selective small-molecule inhibitor of chemokines receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49: 4721-32.
42. Strizki JM, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1, Antimicrob Agents Chemother 2005; 49: 4911-9.
43. Takashima K, Miyake H, Kanzaki N, et al. Highly potent inhibition of human immunodeficiency virus type 1 replication by TAK-220, an orally bioavailable small-molecule CCR5 antagonist. Antimicrob Agents Chemother 2005; 49: 3474-82.
44. Dorr P, Westby M, McFadyen L, et al. PF-232798, a second generation Pfizer oral CCR5 antagonist, in Boston, MA: findings of the 15th Conference on Retroviruses and Opportunistic Infections; 2008 February 3-6: abstract no. 737.
45. Idemyor V. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: Are they the next novel therapies? HIV Clin Trials 2005; 6: 272-7.
46. Balzarini J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm World Soc 1994; 16: 113-26.
47. Daluge SM, Good SS, Faletto MB, et al. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 1997; 41: 1082-93.
48. Gosselin G, Schinazi, RF, Sommadossi JP, et al. Antihuman immunodeficiency virus activities of the beta-L enantiomer of 2β, 3β-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother 1994; 38: 1292-7.
49. Schinazi RF; McMillan A, Cannon D, et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36: 2423-31.
50. De Muys JM, Gourdeau H, Nguyen-Ba N, et al. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2β-deoxy-3β-oxa-4β-thiocytidine. Antimicrob Agents Chemother 1999; 43: 1835-44.
51. Schinazi RF, Chu CK, Peck A, et al. Activities of the four optical isomers of 2β, 3β-dideoxy-3β-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother 1992; 36: 672-6.
52. Lin TS, Luo MZ, Liu MC et al. Antiviral activity of α-L(-)-2β, 3β,-dideoxy-5-fluoro-cytidine (L(-)ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem Pharmacol 1994; 47: 171-4.
53. Cahn P, Cassetti I, Wood R, et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naïve, HIVinfected patients. AIDS 2006; 20: 1261-8.
54. Cox S, Moore S, Southby J, Alsumbe A. Safety Profile of Apricitabine, a Novel NRTI, during 24-Week Dosing in Experienced HIV-1 Infected Patients. Presented at the XVII International AIDS Conference, Mexico City, Mexico, August 3-8 2008; Abstract TUAB0106.
55. Bethell RC, Lie YS, Parkin NT. In vitro activity of SPD754, a new deoxycitidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antiviral Chem Chemother 2005; 16: 295-302.
56. Gu Z, Allard B, de Muys JM, et al. In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother 2006; 50: 625-31.
57. Gallant JE, Straszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviralnaïve patients. A 3-year randomized trial. J Am Med Assoc 2004; 292: 191-201.
58. Cassetti I, Madruga JVR, Suleiman JMAH, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2007; 8: 164-72.
59. Cihlar T, Ray A, Boojamra D, et al. GS9148: A Novel Nucleotide Active against HIV-1 Variants with Drug Resistance Mutations in Reverse Transcriptase. Presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8, 2006, Abstract 45.
60. Baba M, Tanaka H, De Clercq E, et al. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun 1989; 165: 1375-81.
61. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol 2004; 4: 437-46.
62. Pauwels R, Andries K, Desmyter J, et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 1990; 343: 470-4.
63. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990; 250: 1411-3.
64. De Clercq E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present and future. Chem Biodivers 1; 2004: 44-64.
65. Esnouf R, Ren J, Ross C, et al. Nat Struct Biol 1995; 303-8.
66. Sluis-Cremer N, Temiz NA, Bahar I. Cur HIV Res 2004; 10: 323-4.
67. Andries K, de Bethune M-P, Kukla MJ, et al. R165335-TMC125, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) with Nanomolar Activity against NNRTI Resistant HIV Strains. Presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17-20, 2000; Abstract 1840.
68. Dueweke TJ, Poppe SM, Romero DL, et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother 1993; 37: 1127-31.
69. Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int J Biochem Cell Biol 2004; 36: 1735-51.
70. Janssen PA, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[4-[4-[(1E)-2, 6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine), J Med Chem 2005; 48: 1901-9.
71. Flavin MT, Rizzo JD, Khilevich A, et al. Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+)-calanolide A and its enantiomers. J Med Chem 1996; 39: 1303-13.
72. Richman DD, Dousson CB, Storer R, et al. IDX12899 and IDX12989, Novel NNRTI with Potent anti-HIV Activity, Enhanced Barrier to Resistance and Favorable Pharmacokinetic Profile. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 25-28, 2007, Abstract 489.
73. Zhang H, Oberg B, Bottiger D, et al. MIV-150 in a Vaginal Microbicide with Superior Anti-HIV Activities. Presented at the XV International AIDS Conference, Bangkok, Thailand, July 12-16, 2004, Abstract TuPeB4667.
74. Girardet JL, Koh YH, De La Rosa M, et al. The Discovery of RDEA806, a Potent New HIV NNRTI in Phase 1 Clinical Trials. Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20, 2007; Abstract 3285.
75. Sweeney ZK, Klumpp K. Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. Curr Opin Drug Dis Dev 2008; 11: 458-70.
76. Kashman Y, Gustafson KR, Fuller RW, et al. HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivative from the tropical rain forest tree, Calophyllum lanigerum. J Med Chem 1992; 35: 2735-43.
77. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Dis 2005; 4: 236-48.
78. Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem 2001; 276: 23213-6.
79. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008; 51: 5843-55.
80. Molina JM, Hill A. Darunavir (TMC114): a new HIV-1 protease inhibitor. Expert Opin Pharmacother 2007; 8: 1951-64.
81. Temesgen Z, Cainelli F, Vento S. Tipranavir. Drugs Today 2005; 41: 711-20.
82. Bragman K. Sanquinavir. Adv Exp Med Biol 1996; 394: 305-17.
83. Lea AP, Faulds D. Ritonavir. Drugs 1996; 52: 541-6.
84. Plosker, GL, Noble S. Indinavir: a review of its use in the management of HIV infection. Drugs 1999; 58: 1165-203.
85. Tebas P, Powderly WG. Nelfinvir mesylate. Expert Opin Pharmacother 2000; 1: 1429-40.
86. Adkins JC, Faulds D. Amprenavir. Drugs 1998; 55: 837-42.
87. Mangum EM, Graham KK. Lopinavir-ritonavir: a new protease inhibitor. Pharmacotherapy 2001; 21: 1352-63.
88. Becker S, Thornton L. Fosamprenavir: adavancing HIV protease inhibitor treatment options. Expert Opin Pharmacother 2004; 5: 1995-2005.
89. Orrick JJ; Steinhart CR. Atazanavir. Ann Pharmacother 2004; 38: 1664-74.
90. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-90.
91. Tantillo C, Ding J, Jacobo-Molina A, et al. Locations of anti-AIDS drug binding sites and resistance mutations in the threedimensional structure of HIV-1 reverse transcriptase Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994; 243: 369-87.
92. Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy virus-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Pro Nat Aca Sci USA 1986; 83: 1911.
93. Herdewijn P, Balzarini J, De Clercq E, et al. 3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLVIII/ LAV) agents. J Med Chem 1987; 30: 1270.
94. Baba M, Pauwels R, Balzarini J, et al. Selective inhibition of human immunodeficiency virus (HIV) by 3'-azido-2',3'-dideoxyguanosine in vitro. Biophy Res Comm 1987; 145:1080-6.
95. Lin TS, Schinazi RF, Chen MS, et al. Antiviral activity of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) against human immunodeficiency virus in vitro. Biochem Pharmacol 1987; 36: 311-6.
96. Cihlar T, Ray AS. Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine. Ant Res 2010; 85: 39-58.
97. Béthune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989-2009). Antiviral Res 2010; 85: 75-90.
98. Ellison V, Gerton J, Vincent KA, Brown PO. An essential interaction between distinct domains of HIV-1 integrase mediates assembly of the active multimer. J Bio Chem 1995; 270: 3320-6.
99. Engelman A, Bushman FD, Craigie R. Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO Journal 1993; 12: 3269-75.
100. Goldgur Y, Craigie R, Cohen GH, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Pro Nat Aca Sci USA 1999; 96:13040-3.
101. Cai M, Zheng R, Cafferey M, et al. Solution structure of the Nterminal zinc binding domain of HIV-1 integrase (Abstract). Nat Str Bio 1997; 4: 567-77.
102. Burke CJ, Sanyal G, Bruner MW, Ryan JA. Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase. J Bio Chem 1992; 267: 9639-44.
103. Zheng R, Jenkins TM, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Pro Nat Aca Sci USA 1996; 93: 13659-64.
104. Engelman A, Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J Vir 1992; 66: 6361-9.
105. Marchand C, Johnson AA, Karki RG, et al. Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double mutant (F185K/C280S) 2003; 64: 600-9.
106. Marchand C, Zhang X, Pais GC, et al. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J Bio Chem 2002; 277: 12596-603.
107. Chen X, Tsiang M, Yu F, et al. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J Mol Bio 2008; 380: 504-19.
108. Mekouar K, Mouscadet JF, Desmaele D, et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J Med Chem 1998; 41: 2846-57.
109. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-50.
110. Neamati N, Hong H, Owen JM, Sunder S, et al. Salicylhydrazinecontaining inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site. J Med Chem 1998; 41: 3202-09.
111. Nicklaus MC, Neamati N, Hong H, et al. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J Med Chem 1997; 40: 920-9.
112. Zouhiri F, Mouscadet JF, Mekouar K, et al. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem 2000; 43: 1533-40.
113. Wlodawer A, Miller M, Jaskólski M, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989; 245: 616-21.
114. Navia MA, Fitzgerald PMD, McKeever BM, et al. Threedimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989; 337: 615-20.
115. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988; 85: 4686-90.
116. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1988; 331: 280-3.
117. Erickson-Viitanen S, Manfredi J, Viitanen P, et al. Cleavage of HIV-1 gag polyprotein synthesized in vitro: sequential cleavage by the viral protease. AIDS Res Hum Retrovir 1989; 5: 577-91.
118. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich HG. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol 1998; 72: 2846-54.
119. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top. HIV Med 2008; 16: 138-45.
120. Koh Y, Nakata H, Maeda K, et al. Novel bistetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother 2003; 47: 3123-9.
121. Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995; 69: 5228-35.
122. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996; 40, 292-7.
123. Turner SR, Strohbach JW, Tommasi RA, et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41: 3467-76.
124. Piscitelli S, Gallicano K. Interactions among drugs for HIV and opportunistic infections. New Eng J Med 2001; 344: 984-96.
125. Dickinson L, Khoo S, Back D. Pharmacokinetics and drug-drug interactions of antiretrovirals: An update. Antivir Res 2010; 85: 176-89.
126. Hoehe MR, Timmermann B, Lehrach H. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol 2003; 4: 351-78.
127. Tozzi V. Pharmacogenetics of antiretrovirals. Antivir Res 2010; 85: 190-200.
128. Brown DA, London E. Functions of lipid rafts in biological membranes. Ann Rev Cell Dev Biol 1998; 14: 111-36.
129. Pike LJ. Rafts defined: a report on the keystone symposium on lipid rafts and cell function. J Lipid Res 2006; 47(7): 1597-8.
130. Waheed AA, Freed EO. Lipids and membrane microdomains in HIV-1 replication. Virus Res 2009; 143: 162-76.
131. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001; 98(24): 13925-30.
132. Ono A, Waheed AA, Freed EO. Depletion of cellular cholesterol inhibits membrane binding and higher-order multimerization of human immunodeficiency virus type 1 Gag. Virology 2007; 360: 27-35.
133. Brun S, Solignat M, Gay B, et al. VSV-G pseudotyping rescues HIV-1 CA mutations that impair core assembly or stability. Retrovirology 2008; 5: 57.
134. Ozato K, Shin DM, Chang TH, Morse 3rd HC. TRIM family proteins and their emerging roles in innate immunity. Nat Rev Immunol 2008; 8(11): 849-60.
135. Klumpp K, Mirzadegan T. Recent progress in the design of small molecule inhibitors of HIV RNase H. Curr Pharm Des 2006; 12(15): 1909-22.
136. Jochmans D. Novel HIV-1 reverse transcriptase inhibitors. Virus Res. 2008; 134(1-2): 171-85.
137. Tisdale M, Schulze T, Larder BA, Moelling K. Mutations within the RNaseH domain of human immunodeficiency virus type 1 re verse transcriptase abolish virus infectivity. J Gen Virol 1991; 72 (Pt 1): 59-66.
138. Cherepanov P, Sun ZY, Rahman S, Maertens G, Wagner G, Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat Struct Mol Biol 2005; 12 (6): 526-32.
139. Adamson CS, Freed EO. Novel approaches to inhibiting HIV-1 replication. Antiviral Research 2010; 85: 119-41.
140. Gorelick RJ, Nigida Jr. SM, Bess Jr. JW, Arthur LO, Henderson LE, Rein A. Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J Virol 1990; 64(7): 3207-11.
141. Levin JG, Guo J, Rouzina I, Musier-Forsyth K. Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog Nucl Acid Res Mol Biol 2005; 80: 217-86.
142. Lee SK, Harris J, Swanstrom R. A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an achilles heel in the virus life cycle. J Virol 2009; 83(17): 8536-43.
143. Adamson CS, Salzwedel K, Freed EO. Virus maturation as a new HIV-1 therapeutic target. Expert Opin Ther Targets 2009; 18: 895-908.
144. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.C.O.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000; 14: 499-507.
145. Hawkins T. Understanding and managing the adverse effects of antiretroviral therapy. Antivir Res 2010; 85: 201-9.
146. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997; 51: 151-78.
147. Quinones-Mateu ME, Arts EJ. Fitness of drug resistant HIV-1: Methodology and clinical implications. Drug Resist Updat 2002; 5: 224-33.
148. Paredes C, Clotet B. Clinical management of HIV-1 resistance. Antivir Res 2010; 85: 245-65.
149. Dahl V, Josefsson L, Palmer S. HIV reservoirs, latency and reactivation: Prospects for eradication. Antivir Res 2010; 85: 286-94.